Valmark Advisers Inc. boosted its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 107.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,605 shares of the company’s stock after acquiring an additional 1,351 shares during the period. Valmark Advisers Inc.’s holdings in Elevance Health were worth $1,013,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Elevance Health in the 2nd quarter worth approximately $7,344,424,000. State Street Corp boosted its holdings in Elevance Health by 1.3% in the 2nd quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after purchasing an additional 137,914 shares during the period. Wellington Management Group LLP grew its position in shares of Elevance Health by 12.0% during the 2nd quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after purchasing an additional 984,976 shares in the last quarter. First Eagle Investment Management LLC grew its position in shares of Elevance Health by 1.4% during the 2nd quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock valued at $1,619,701,000 after purchasing an additional 55,905 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Elevance Health in the second quarter worth $1,246,349,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $451.00 price target on shares of Elevance Health in a report on Friday, October 23rd. Barclays lifted their price objective on Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Mizuho set a $490.00 target price on Elevance Health in a research report on Friday, October 23rd. Royal Bank Of Canada upped their target price on Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Elevance Health in a research note on Wednesday. Fifteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $456.48.
Get Our Latest Analysis on ELV
Insider Buying and Selling at Elevance Health
In other news, EVP Ratnakar Lavu sold 1,300 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the transaction, the executive vice president directly owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer owned 19,919 shares in the company, valued at approximately $8,766,949.47. This represents a 34.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.34% of the company’s stock.
Elevance Health Trading Down 0.0%
ELV stock opened at $429.50 on Monday. The company has a market capitalization of $92.80 billion, a PE ratio of 18.32, a price-to-earnings-growth ratio of 2.05 and a beta of 0.63. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69. The company’s 50 day moving average price is $415.40 and its two-hundred day moving average price is $375.20. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47.
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The firm had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same period in the previous year, the business posted $6.03 EPS. The business’s quarterly revenue was up .7% on a year-over-year basis. As a group, analysts predict that Elevance Health, Inc. will post 29.15 earnings per share for the current fiscal year.
Elevance Health Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s dividend payout ratio (DPR) is presently 29.34%.
Elevance Health Profile
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
See Also
- Five stocks we like better than Elevance Health
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
